Chloroquine efficacy for plasmodium vivax in ethiopia pdf

Chloroquine efficacy for plasmodium vivax in ethiopia pdf
This research is intended to study the efficacy of chloroquine (CQ) and primaquine (PQ) for Plasmodium vivax (P.vivax) infection, and also to study the recurrence rate among patients with P.vivax malaria on standard doses of CQ and PQ.
Chloroquine is an anti-malarial drug being used to treat Plasmodium vivax malaria cases in Ethiopia. However, emergence of chloroquine resistant strains of the parasite has challenged the current efficacy of the drug. Therefore, the aim of this study was to assess the effectiveness of chloroquine
Using the search terms “vivax” and “chloroquine”, MEDLINE, Web of Science, Embase, and the Cochrane Database of Systematic Reviews were searched for articles published before Nov 29, 2017, that assessed the efficacy of chloroquine, with or without primaquine, for uncomplicated Plasmodium vivax …
The present study (CTRI/2011/09/002031) was designed to investigate the therapeutic efficacy of chloroquine and chloroquine plus primaquine in P. vivax malaria and the polymorphisms of the pvmdr1 and pvcrt-o genes associated with it.
Charles Darwin University Chloroquine efficacy for Plasmodium vivax in Myanmar in populations with high genetic diversity and moderate parasite gene flow
Background. Plasmodium vivax accounts for about 40% of all malaria infection in Ethiopia. Chloroquine (CQ) is the first line treatment for confirmed P. vivax malaria in the country.
Abreha T, Hwang J, Thriemer K, et al. Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: A randomized controlled trial. PLoS Med 2017; 14:e1002299.
In Ethiopia, malaria is caused by both Plasmodium falciparum and Plasmodium vivax. Drug Drug resistance of P. falciparum to sulfadoxine-pyrimethamine (SP) and chloroquine (CQ) is
The investigators hypothesize that the addition of primaquine (PQ) to both artemether-lumefantrine (AL) and chloroquine (CQ) for the treatment of Plasmodium vivax infection will result in decreased chance of relapse by about 60%.
Plasmodium vivax accounts for about 44 % of all malaria infection in Ethiopia. Chloroquine (CQ) is the first-line treatment for vivax malaria in Ethiopia. Chloroquine-resistant (CQR) P. vivax has been emerging in different parts of the world to compromise the efficacy of the drug and pose both
Plasmodium vivax malaria. Compared with chloroquine, We assessed the efficacy of standard 3-day courses of chloroquine and DHA/PPQ for treating P. vivax malaria, preventing recurrences, and blocking human-to-mosquito transmission. The Study We conducted an open-label, randomized, control trial in June–December 2014 in Rattanakiri Province, Cambodia. Febrile patients or patients with a
Chloroquine is the first-line drug for treatment of P. vivax in most areas of the world (World Health Organization 1997), although artemisinin and derivatives are also used in various regimens and they appear to be effective (Nguyen et al. 1993).
Background. Chloroquine (CQ) is the first-line treatment for vivax malaria in Ethiopia, but there is evidence for its declining efficacy. Defining the extent and regional distribution of CQ resistance is critical to ensure optimal treatment guidelines.
BackgroundChloroquine (CQ) is the first-line treatment for vivax malaria in Ethiopia, but there is evidence for its declining efficacy. Defining the extent and regional distribution of CQ resistance is critical to ensure optimal treatment guidelines. This study aimed to provide data on the therapeutic efficacy of CQ against Plasmodium vivax malaria in southern Ethiopia.MethodsPatients with P
RESEARCH Open Access Therapeutic efficacy of chloroquine for treatment of Plasmodium vivax malaria cases in Halaba district, South Ethiopia Tsige Ketema1*, Kefelegn Getahun2 and …
SOURCE: Chu CS, Phyo AP, Lwin KM, et al. Comparison of the cumulative efficacy and safety of chloroquine, artesunate, and chloroquine-primaquine in Plasmodium vivax malaria. Clin Infect Dis 2018;67:1543-1549.
Vivax malaria relapses are predominantly delayed by chloroquine (CQ) but prevented by primaquine (PMQ), according to a study published in Clinical Infectious Diseases. Plasmodium vivax exerts considerable morbidity by causing repeat relapses.
The efficacy of chloroquine in the treatment of Plasmodium vivax malaria is declining on the Northwestern border of Thailand. This randomized controlled trial in 500 adults and children shows that dihydroartemisinin-piperaquine is a safe and effective alternative treatment

Therapeutic efficacy of chloroquine for treatment of <it

RESEARCH Open Access Return of chloroquine-sensitive
the treatment of Plasmodium vivax infection in Ethiopia: A randomized controlled trial Tesfay Abreha 1 ☯ , Jimee Hwang 2,3 , Kamala Thriemer 4 ☯ * , Yehualashet Tadesse 1 ,
First-line treatment for Plasmodium vivax (Pv) is with chloroquine (CQ) alone without primaquine therapy in malarious areas. For all clinical infection without laboratory confirmation, AL which is effective against both Pf and Pv is the first-line treatment. Thus, in Ethiopia, where treatment for malaria without laboratory confirmation occurs frequently, Pv is often treated with AL as the
recommended for the treatment of malaria because high-grade chloroquine- resistant P. falciparum malaria has spread to most malaria-endemic areas of the world, and high-grade chloroquine-resistant Plasmodium vivax malaria occurs
chloroquine (CQ) without primaquine is the first-line treatment for Plasmodium vivax in malarious areas, but artemether- lumefantrine (AL) is also commonly used. Methods and Findings:In 2009, we conducted a 42-day efficacy study of AL or CQ for P. vivax in Oromia Regional State,
3/07/2017 · Conclusions. On the basis of this review, anti-malarial treatment success was high (92.9%) and standard regimens showed good efficacy against Plasmodium falciparum (98.1%) and P. vivax (94.7%) infections in Ethiopia, but associated with high rates of adverse drug reactions (ADRs).
Chloroquine-resistant Plasmodium vivax malaria in Debre Zeit, Ethiopia By Hiwot Teka, Beyene Petros, Lawrence Yamuah, Gezahegn Tesfaye, Ibrahim Elhassan, Simon Muchohi, Gilbert Kokwaro, Abraham Aseffa and Howard Engers
Chloroquine or dihydroartemisinin-piperaquine with either a 7- or 14-day primaquine regimen provided highly effective radical cure of Plasmodium vivax malaria on the Thailand-Myanmar border, suggesting that short-course and higher-dose primaquine regimens for P vivax malaria radical cure may aid efficacy by improving adherence, according to a
Previous article in issue: Chloroquine resistance of Plasmodium falciparum malaria in Ethiopia and Eritrea Previous article in issue: Chloroquine resistance of Plasmodium falciparum malaria in Ethiopia and Eritrea Next article in issue: Severe falciparum malaria with …
Plasmodium vivax is the most widespread human malaria parasite. Almost 2.5 billion persons are at risk for infection in >90 countries (1,2). Since the 1950s–1960s, Southeast Asia has been the cradle of emergence and spread of P. falciparum antimalarial drug resistance, a major obstacle for malaria control.
Background: Fever is the main complaint in patients reporting to our hospital and the most common cause of fever in our set up is malaria. The aim of this study was to know about the clinical response, efficacy and resistance of vivax malaria to chloroquine in patients reporting to Thall Scouts Hospital.

Emerging resistance to chloroquine (CQ) by Plasmodium vivax threatens the health of the hundreds of millions of people routinely exposed to the risk of infection with this organism. CQ has been the first-line therapy for vivax malaria since 1946 ( 32 , 115 ).
Background In vivo efficacy assessments of antimalarials are essential for ensuring effective case management. In Ethiopia, chloroquine (CQ) without primaquine is the first-line treatment for Plasmodium vivax in malarious areas, but artemether-lumefantrine (AL) is also commonly used.
The erosion to collapse of chloroquine efficacy in Indonesia and the spread of the problem into South and Southeast Asia, where the vast majority of vivax malaria occurs, commands attention to the observations of Alving and colleagues . The strategy of replacing chloroquine on the basis of efficacy against the asexual blood stages alone requires reassessment. The synergistic effect of quinine
Return of chloroquine-sensitive Plasmodium falciparum parasites and emergence of chloroquine-resistant Plasmodium vivax in Ethiopia Seleshi Kebede Mekonnen1,2,3,7*, Abraham Aseffa2, Nega …

Plasmodium vivax accounts for about 44 % of all malaria infection in Ethiopia. Chloroquine (CQ) is the first-line treatment for vivax malaria in Ethiopia.
BackgroundChloroquine (CQ) is the first-line treatment for vivax malaria in Ethiopia, but there is evidence for its declining efficacy. Defining the extent and regional distribution of CQ resistance is critical to ensure optimal treatment guidelines. This study aimed to provide data on the
Chloroquine (CQ) is the first line treatment for confirmed P. vivax malaria in the country. The first report of CQ treatment failure in P. vivax was from Debre Zeit, which suggested the presence of chloroquine resistance.

Methods

An in vivo drug efficacy study was conducted in Debre Zeit from June to August 2006. Eighty-seven patients with
The recent drive to rid the world of malaria has brought P vivax to the fore, with the recognition that relapses pose a serious obstacle to its eradication, and with a recommendation that chloroquine and primaquine should be combined as a first-line treatment.
At least one con rmed case of chloroquine-resistant vivax malaria was reported in Brazil, Ethiopia, Indonesia, Malaysia (Borneo), Myanmar, Solomon Islands, Thailand, Papua …

Abstract

Background

Chloroquine is an anti-malarial drug being used to treat Plasmodium vivax malaria cases in Ethiopia. However, emergence of chloroquine resistant strains of the parasite has challenged the current efficacy of the drug. Therefore, the aim of this study was to assess the effectiveness of chloroquine against P. vivax strains in one of the
Plasmodium vivax . Malaria: Global Health Problem. CO-4 Single-dose tafenoquine (TQ) 300 mg in combination with standard chloroquine (CQ) Efficacious treatment for relapse prevention of . P. vivax
Background: Chloroquine (CQ) is the first-line treatment for vivax malaria in Ethiopia, but there is evidence for its declining efficacy. Defining the extent and regional distribution of CQ resistance is critical to ensure optimal treatment
This study therefore, assessed the therapeutic efficacy of Chloroquine (CQ) for the treatment of Plasmodium vivax infections in Northwestern Ethiopia. Methods An observational, 28- day therapeutic clinical efficacy study was conducted from August to December, 2014, in Northwest Ethiopia.
Resistance to Chloroquine Unhinges Vivax Malaria
EFFICACY OF CHLOROQUINE FOR VIVAX MALARIA IN THAILAND Vol 35 No. 3 September 2004 567 3 days (300 mg, three times, at 6-hourly inter-vals, on the 1 st day, followed by 300 mg daily for
Conclusions. On the basis of this review, anti-malarial treatment success was high (92.9%) and standard regimens showed good efficacy against Plasmodium falciparum (98.1%) and P. vivax (94.7%) infections in Ethiopia, but associated with high rates of adverse drug reactions (ADRs).
Chloroquine has been recommended for Plasmodium vivax infections for >60 years, but resistance is increasing. To guide future therapies, the cumulative benefits of using slowly eliminated (chloroquine) vs rapidly eliminated (artesunate) antimalarials, and the risks and benefits of adding radical cure (primaquine) were assessed in a 3-way randomized comparison conducted on the Thailand-Myanmar – example of effective communicator with strong written skills PDF Chloroquine (CQ) is the first-line treatment for vivax malaria in Ethiopia, but there is evidence for its declining efficacy. Defining the extent and regional distribution of CQ resistance
A survey of compliance, efficacy and side effects of malaria prophylaxis identified a cluster of infection in a cohort of 33 travellers to Ethiopia 32% of whom developed P. vivax malaria. Of those taking Mefloquine and Doxycycline as prophylaxis 50% and 66% respectively subsequently developed P. vivax , compared to none taking Atovaquone/Proguanil.
Background. Although, Plasmodium vivax is a rare parasite in most parts of Africa, it has significant public health importance in Ethiopia. In some parts of the country, it is responsible for majority of malaria associated morbidity.
Chloroquine (CQ) is the first-line treatment for vivax malaria in Ethiopia, but there is evidence for its declining efficacy. Defining the extent and regional distribution of CQ resistance is critical to ensure optimal treatment guidelines. This study aimed to provide data on the therapeutic
drug efficacy studies conducted in Ethiopia and to use the findings to formulate recommendations for antimalarial drug efficacy monitoring and use of evidence to inform antimalarial treatment policy for the Ethiopian setting.
Chloroquine (CQ) is the drug of choice for the treatment of Plasmodium vivax infection in the country, although CQ resistant P. vivax (CRPv) has started to challenge the efficacy of the drug. The present study was conducted to assess the current status of CRPv at Serbo, Jimma zone, south-west Ethiopia. Methods: A 28-day in vivo therapeutic efficacy test was conducted from October 2007 to
Plasmodium vivax IN BRAZILIAN AMAZON Ana Yecê das Neves PINTO(1), Carolina Heitmann AZEVEDO(2), Janaína Bezerra da SILVA(2) & José Maria de SOUZA(1) SUMMARY Malaria regions of the Amazon basin have been characterized by difficult access and non-compliance of the patients to treatment. In an attempt to assess the schizonticide efficacy of chloroquine in a single dose of 600 …
Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: A …
Chloroquine-resistant falciparum malaria was first documented in Papua New Guinea (PNG) in 1976 (1,2). Since then, studies done in different provinces at different times showed the problem to be widespread and to increase gradually with a slow gradual shift Parasitological and clinical efficacy of standard treatment regimens against Plasmodium falciparum, P. vivax and P. malariae in Papua …
July 2016, Vol. 45 No. 7 Effi cacy of Chloroquine for P. Vivax—Hariharan Subramony et al 304 Since P. vivax may exist in a dormant form in the liver
Plasmodium vivax is the second most important cause of morbidity in Ethiopia. There is, however, little information on P. vivax resistance to chloroquine and chloroquine plus primaquine treatment although these drugs have been used as the first line treatment for over 50 years.
Therapeutic efficacy of chloroquine for treatment of Plasmodium vivax malaria cases in Halaba district, South Ethiopia . Chloroquine-resistant Plasmodium vivax malaria in Serbo town, Jimma zone, south-west Ethiopia. Malaria J (2004). British pharmacopeia; (1946). Chloroquine for the treatment of acute attacks of vivax malaria.
Background: Evidence for decreasing chloroquine (CQ) efficacy against Plasmodium vivax has been reported from many endemic countries in the world. In Ethiopia, P. vivax accounts for 40% of all malaria cases and CQ is the first-line drug for vivax malaria. Mutations in multidrug resistance 1 (pvmdr-1) and K10 insertion in the pvcrt-o genes have been identified as possible molecular markers of
Reference. 1. Abreha T, Hwang J, Thriemer K, Tadesse Y, Girma S, Melaku Z, et al. (2017) Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: A randomized controlled trial.
Abstract. Background: This study aimed to synthesize available evidence on the efficacy of dihydroartemisinin-piperaquine (DHP) in treating uncomplicated Plasmodium vivax malaria in people living in endemic countries.
Malaria regions of the Amazon basin have been characterized by difficult access and non-compliance of the patients to treatment. In an attempt to assess the schizonticide efficacy of chloroquine in a single dose of 600 mg, the authors realized a double-blind, placebo-controlled trial in 132 outpatients with vivax …
AbstractIn most regions of the world, chloroquine (CQ) has been the standard treatment for Plasmodium vivax malaria for more than 40 years. Recently, however, CQ-resistant P. vivax has been reported from Oceania, several parts of Asia, and South America. The therapeutic efficacy of CQ in the treatment of acute, P. vivax malaria has now been
Polymorphisms in chloroquine resistance-associated genes in Plasmodium vivax in Ethiopia Diagnosis and Treatment of Plasmodium vivax Malaria Diagnosis and Treatment of Plasmodium vivax Malaria In Vivo Efficacy of Artemether-Lumefantrine and Chloroquine against Plasmodium vivax: A Randomized Open Label Trial in Central Ethiopia
Background: Chloroquine (CQ) is the first-line treatment for vivax malaria in Ethiopia, but there is evidence for its declining efficacy. Defining the extent and regional distribution of CQ resistance is critical to ensure optimal treatment guidelines.
Safety & Efficacy of Chloroquine & Primaquine for Vivax
(2010) Efficacy and safety of chloroquine for treatment in patients with uncomplicated Plasmodium vivax infections in endemic countries. Transactions of the Royal Society of Tropical Medicine and Hygiene 104 :11, 695-705.
Abstract. The blood stage antimalarial efficacy of primaquine (0.25 mg of base/kg of body weight/day over 14 days) and chloroquine (25 mg of base/kg over 3 days) were compared in 85 adult Thai men with acute Plasmodium vivax malaria.
Rieckmann KH, Davis DR, Hutton DC: Plasmodium vivax resistant Chloroquine-resistant P. vivax parasites are emerging in to chloroquine? Lancet 1989, 2:1183-1184. 5. Baird JK, Basri H, Purnomo , Bangs MJ, Subianto B, Patchen LC, Hoff- Debre Zeit, Ethiopia. There is a need for regular monitor- man SL: Resistance to chloroquine by Plasmodium vivax in ing of the pattern of resistance to
In VivoEfficacy of Artemether-Lumefantrine and Chloroquine

Radical Curative Efficacy of Five-Day Regimen of

Efficacy of Chloroquine for the Treatment of Vivax malaria

Therapeutic efficacy of chloroquine for the treatment of

Chloroquine-resistant Plasmodium vivax malaria in Debre

Chloroquine resistant Plasmodium vivax malaria in India

Polymorphisms in chloroquine resistance-associated genes
– Comparison of the Cumulative Efficacy and Safety of
Welcome to CDC stacks In Vivo Efficacy of Artemether

Chloroquine-resistant Plasmodium vivax malaria in

Correction Comparison of artemether-lumefantrine and

(PDF) Chloroquine efficacy for Plasmodium vivax malaria
Short Course Primaquine Regimens for P vivax Malaria

the treatment of Plasmodium vivax infection in Ethiopia: A randomized controlled trial Tesfay Abreha 1 ☯ , Jimee Hwang 2,3 , Kamala Thriemer 4 ☯ * , Yehualashet Tadesse 1 ,
Chloroquine has been recommended for Plasmodium vivax infections for >60 years, but resistance is increasing. To guide future therapies, the cumulative benefits of using slowly eliminated (chloroquine) vs rapidly eliminated (artesunate) antimalarials, and the risks and benefits of adding radical cure (primaquine) were assessed in a 3-way randomized comparison conducted on the Thailand-Myanmar
Abstract. Background: This study aimed to synthesize available evidence on the efficacy of dihydroartemisinin-piperaquine (DHP) in treating uncomplicated Plasmodium vivax malaria in people living in endemic countries.
BackgroundChloroquine (CQ) is the first-line treatment for vivax malaria in Ethiopia, but there is evidence for its declining efficacy. Defining the extent and regional distribution of CQ resistance is critical to ensure optimal treatment guidelines. This study aimed to provide data on the
Plasmodium vivax IN BRAZILIAN AMAZON Ana Yecê das Neves PINTO(1), Carolina Heitmann AZEVEDO(2), Janaína Bezerra da SILVA(2) & José Maria de SOUZA(1) SUMMARY Malaria regions of the Amazon basin have been characterized by difficult access and non-compliance of the patients to treatment. In an attempt to assess the schizonticide efficacy of chloroquine in a single dose of 600 …

Therapeutic and Transmission-Blocking Efficacy of
Chloroquine efficacy for Plasmodium vivax malaria

Background: Evidence for decreasing chloroquine (CQ) efficacy against Plasmodium vivax has been reported from many endemic countries in the world. In Ethiopia, P. vivax accounts for 40% of all malaria cases and CQ is the first-line drug for vivax malaria. Mutations in multidrug resistance 1 (pvmdr-1) and K10 insertion in the pvcrt-o genes have been identified as possible molecular markers of
Background. Plasmodium vivax accounts for about 40% of all malaria infection in Ethiopia. Chloroquine (CQ) is the first line treatment for confirmed P. vivax malaria in the country.
EFFICACY OF CHLOROQUINE FOR VIVAX MALARIA IN THAILAND Vol 35 No. 3 September 2004 567 3 days (300 mg, three times, at 6-hourly inter-vals, on the 1 st day, followed by 300 mg daily for
Abstract. The blood stage antimalarial efficacy of primaquine (0.25 mg of base/kg of body weight/day over 14 days) and chloroquine (25 mg of base/kg over 3 days) were compared in 85 adult Thai men with acute Plasmodium vivax malaria.
Vivax malaria relapses are predominantly delayed by chloroquine (CQ) but prevented by primaquine (PMQ), according to a study published in Clinical Infectious Diseases. Plasmodium vivax exerts considerable morbidity by causing repeat relapses.
Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: A …
In Ethiopia, malaria is caused by both Plasmodium falciparum and Plasmodium vivax. Drug Drug resistance of P. falciparum to sulfadoxine-pyrimethamine (SP) and chloroquine (CQ) is
July 2016, Vol. 45 No. 7 Effi cacy of Chloroquine for P. Vivax—Hariharan Subramony et al 304 Since P. vivax may exist in a dormant form in the liver
The present study (CTRI/2011/09/002031) was designed to investigate the therapeutic efficacy of chloroquine and chloroquine plus primaquine in P. vivax malaria and the polymorphisms of the pvmdr1 and pvcrt-o genes associated with it.